This site is intended for healthcare professionals

CanSinoBIO announces approval for its MCV4 meningococcal vaccine Menhycia in China.

Read time: 1 mins
Published:18th Jan 2022
CanSino Biologics Inc. announced that the National Medical Products Administration of China granted approval for its ACYW135 Meningococcal Conjugate Vaccine (CRM197) (“MCV4”, trade name: Menhycia), making it the first of its kind to be authorized in China.

The approval marks an important step in accelerating the development of China’s meningococcal vaccine immunization strategy. Menhycia provides protection for a wide range of age groups, including for children aged 3 months to 3 years old (47 months), by inducing strong T cell immune responses and immunological memory for immunized children.

Menhycia covalently binds common pathogenic meningococcal serogroups A, C, W135 and Y to the carrier protein CRM197. Currently, Menhycia is the initial vaccine product containing these four serogroups in China.

Condition: Meningococcal Disease
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.